IRON-II Study Uses 454 Sequencing to Investigate New Markers for Hematological Malignancies | GenomeWeb

A consortium of mostly European laboratories is in the midst of investigating new markers for hematological cancers using amplicon deep sequencing.

The research study, called IRON-II, for Interlaboratory Robustness of Next-generation sequencing, is supported by Roche and uses the 454 platform. A follow-on to an earlier study to test the technical performance of amplicon deep sequencing in different laboratories, the new study is investigating panels of one to 25 genes in a total of 6,000 to 8,000 retrospective samples covering five hematological malignancies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.